Synthetic Cannabinoids (K2, Spice) and Ketamine Therapy | Tovani Health
K2 (Synthetic Cannabinoids) (also: Spice, AB-FUBINACA, AMB-FUBINACA, JWH-018) — Synthetic CB1 full agonists (DEA Schedule I; recreational use illegal)
Verdict at Tovani Health
Full-agonist CB1 activity with documented seizure, MI, and psychiatric toxicity; do not combine.
Synthetic cannabinoids (K2, Spice, etc.) are NOT pharmacologically similar to cannabis despite the marketing. They are full CB1 receptor agonists (THC is only a partial agonist), often 100x more potent at the receptor. Documented harms include seizures, myocardial infarction in young patients, acute kidney injury, hyperthermia, and severe psychotic episodes — sometimes from a single use. Product composition is unregulated and varies wildly between batches. Stacking with ketamine adds unpredictable cardiovascular and CNS effects on top of already-unpredictable pharmacology. Recent use disqualifies any ketamine session.
If you take K2 regularly, at-home ketamine therapy isn't currently a fit — see below for why and what would need to change. This page covers the brief pharmacologic context and what we do at intake.
How K2 interacts with ketamine
Synthetic cannabinoids fully activate CB1 receptors, producing more intense and prolonged effects than THC's partial agonism. The chemical structures change rapidly as compounds are scheduled, with newer variants often more potent and less predictable. Cardiac toxicity, seizures, and acute psychosis are well-documented even in first-time users.
What we do at intake
Honest disclosure matters. We require at least 2-4 weeks of abstinence and individualized evaluation. For young patients with recent synthetic cannabinoid use, also rule out cardiac or renal events.
Bottom line
Synthetic cannabinoids (K2, Spice, etc.) are NOT pharmacologically similar to cannabis despite the marketing. They are full CB1 receptor agonists (THC is only a partial agonist), often 100x more potent at the receptor. Documented harms include seizures, myocardial infarction in young patients, acute kidney injury, hyperthermia, and severe psychotic episodes — sometimes from a single use. Product composition is unregulated and varies wildly between batches. Stacking with ketamine adds unpredictable cardiovascular and CNS effects on top of already-unpredictable pharmacology. Recent use disqualifies any ketamine session.
What would change this answer
We don’t prescribe at-home ketamine in this scenario today, but the situation can change. Talk to your prescribing physician about whether the underlying clinical picture (medication change, dose taper, indication shift, or stabilization milestone) might make you eligible later. We’re happy to revisit if your circumstances change.
For immediate mental health support, the 988 Suicide & Crisis Lifeline is available 24/7 (call or text 988).
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- The synthetic cannabinoids menace: a review of health risks and toxicity. Alzu'bi A, Almahasneh F, Khasawneh R. European Journal of Medical Research. 2024. PMID: 38216984
- Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review. de Oliveira MC, Vides MC, Lassi DLS. Brain Sciences. 2023. PMID: 37508922
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 22, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.